Competitor Recall Continues To Show Opportunities For ResMed
ResMed Inc (NYSE: RMD ) posted Q4 sales of $914.7 million , 4% Y|Y ( 8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to … Full story available on Benzinga.com
Competitor Recall Continues To Show Opportunities For ResMed
ResMed Inc (NYSE: RMD ) posted Q4 sales of $914.7 million , 4% Y|Y ( 8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to … Full story available on Benzinga.com